A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract

Immune checkpoint blockade has made a significant impact on the clinical outcomes of patients with metastatic urothelial carcinoma (UC). However, evidence for this approach in patients with non‐UC of the urinary tract is limited.

[1]  T. Choueiri,et al.  Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies , 2020, Cancer.

[2]  Craig B. Davis,et al.  Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. , 2020, The New England journal of medicine.

[3]  S. Steinberg,et al.  Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Milowsky,et al.  Histologic Variants of Urothelial Carcinoma: Morphology, Molecular Features and Clinical Implications , 2020, Bladder Cancer.

[5]  A. Gasbarrini,et al.  Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). , 2020 .

[6]  G. Kristiansen,et al.  Comparative genomic profiling of glandular bladder tumours , 2020, Virchows Archiv.

[7]  M. Rose,et al.  Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation , 2020, BMC Cancer.

[8]  V. Miller,et al.  Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. , 2020, European urology.

[9]  P. Ascierto,et al.  Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  Y. Lotan,et al.  Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. , 2019, Urologic oncology.

[11]  Y. Bang,et al.  Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma , 2019, Clinical Cancer Research.

[12]  Myung Ah Lee,et al.  Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.

[13]  K. Syrigos,et al.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.

[14]  T. Powles,et al.  Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. , 2019, European urology.

[15]  K. Goldberg,et al.  Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Choueiri,et al.  Phase II study of nivolumab and ipilimumab for advanced bladder cancer of variant histologies (BCVH). , 2019, Journal of Clinical Oncology.

[17]  P. Ascierto,et al.  Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Culine,et al.  Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma , 2019, Case Medical Research.

[20]  M. Sydes,et al.  BA08: An open-label, single-arm, non-randomised, phase 2 trial of cisplatin, methotrexate and vinblastine (CMV) for pure squamous cell cancer of the urinary tract , 2019, PloS one.

[21]  C. Brennan,et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.

[22]  B. Rini,et al.  Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. , 2018, Urologic oncology.

[23]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[24]  M. Berger,et al.  Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Sawyer,et al.  Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142. , 2018 .

[26]  T. Powles,et al.  A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901). , 2018 .

[27]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[28]  G. Iyer,et al.  Molecular Alterations in the Pathogenesis of Bladder Cancer Subtypes and Urothelial Carcinoma Variants , 2018 .

[29]  N. Socci,et al.  Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis , 2017, Clinical Cancer Research.

[30]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.

[31]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[32]  Wayne L Ernst,et al.  Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma , 2017, Modern Pathology.

[33]  T. Curiel,et al.  Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Holger Moch,et al.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. , 2016, European urology.

[35]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[36]  J. Cheville,et al.  Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis. , 2013, The Journal of urology.

[37]  S. Culine,et al.  Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Joon-Oh Park,et al.  Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract , 2009, Medical oncology.

[39]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[40]  P. Russo,et al.  Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. , 2007, Urology.

[41]  Y. Lotan,et al.  Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. , 2006, The Journal of urology.

[42]  F. Guillé,et al.  Non‐transitional cell bladder carcinomas , 2005, BJU international.

[43]  M. Mazumdar,et al.  Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.